Abstract
The introduction of the adenosine deaminase (ADA) gene into mature lymphocytes of a patient with ADA deficiency offers only a temporary treatment of the immunodeficiency but has paved the way for potential cure of this and other inherited diseases through the use of somatic gene therapy. Rapid progress in the development of molecular technology has resulted in the identification of a number of disease genes, the subsequent cloning of their normal counterparts, and has enabled scientists to address correction of these inherited disorders. Large amounts of gene products can now be produced by recombinant technology and initial therapeutic efforts focused on the in vivo administration of such purified recombinant proteins. This therapeutic approach has been ineffective in the treatment of genetic diseases in which the activity of the enzyme is located within the cell, with the notable exceptions of ADA deficiency and Gaucher disease (1). Even when addition of the deficient enzyme has been found to correct the biochemical defect in vitro, in vivo administration of the enzyme has generally not proven to be adequate therapy for correction of the defect due to either accelerated metabolism of the protein or an enhanced immune response to the protein. Research efforts in the correction of inherited defects have thus been directed to the transfer of normal genes to autologous target cells and the reintroduction of these cells into the patient. The use of various strategies to transfer genetic sequences into somatic cells from patients and their readministration to the patient for clinical benefits constitutes somatic gene therapy (2). The requirements for a successful gene therapy protocol include: (i) identification and availability of the defective gene (cloned) (ii) knowledge of the biology and regulation of the gene in the target tissue and (iii) the ability to transduce sufficient numbers of target cells as well as ensuring proper gene regulation. Although most commonly considered in the context of inherited single gene defects because of the extensive molecular knowledge of the defective gene and target cell involved, gene therapy plays an increasingly greater role in the therapy of acquired diseases, as the genes and target cells involved in these disorders are identified and new methods of gene transfer are developed.
Keywords
- Human Immunodeficiency Virus
- Gene Therapy
- Gauche Disease
- Glycogen Storage Disease
- Maple Syrup Urine Disease
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Levy, Y., Hershfield, M.S., Fernandez, M.C., Polmar, S.H., Scudiery, D., Berger, M. and Sorensen, R.U. (1988) J. Pediat. 113, 312–317.
Mulligan, R. (1991) in Etiology of Human Disease at the DNA Level (J. Lindsten and U. Pettersson, eds.), pp. 143–189, Raven Press, New York, NY.
Collins, F.S. (1991) Hospital Practice 26, 93–98.
Belmont, J. and Caskey, C.T. (1986) in Gene Therapy (R. Kurcherlapati, ed.), pp. 411–420, Plenum Press, New York, NY.
Bach, F.H., Albertini, R.J. and Joo, P. (1968) Lancet 2, 1364–1366.
O’Reilly, R.J., Brochstein, J., Dinsmore, R. and Kirkpatrick, D. (1984) Semin. Hematol. 21, 188–221.
Langlois, R.P., O’Regan, S., Pelletier, M. and Robitaille, P. (1981) Nephron 28, 273–278.
O’Reilly, R.J., Keever, C.A., Small, T.N. and Brochstein, J. (1989) Immunodef. Rev. 1, 273–309.
Luccarelli, G., Galimberti, M., Polchi, P. Angelucci, E., Baronnoni, D., Giardini, C., Politi, F., Durazzi, S.M., Morello, P. and Albertini, T. (1990) N. Engl. J. Med. 322, 417–421.
Vermylen, C., Fernandez-Robles, E., Ninane, J. and Cornu, G. (1988) Lancet 21, 1427–1428.
O’Reilly, R.J. (1991) in Etiology of Human Disease at the DNA Level (J. Lindsten and U. Pettersson, eds.), pp. 261–289, Raven Press, New York, NY.
Broxmeyer, H.E., Douglas, G.W., Hangoc, G., Cooper, S., Bard, J., English, D., Arny, M., Thomas, L. and Boyse, E.A. (1989) Proc. Nat. Acad. Sci. U.S.A. 86, 3828–3832.
Gerritsen, E.J.A., Van Loo, I.H.G. and Fisher, A. (1990) Bone Marrow Transplantation 5 (Supp. 2), 12.
Thomas, E.D., Ramberg, R.F. and Sale, G.E. (1976) Science 192, 1016–1018.
Nyhan, W.L., Page, T., Gruber, H.E. and Parkman, R. (1986) Birth Defects 22, 41–53.
Sutherland, H.J., Lansdorp, P.M., Henkelman, D.H., Eaves, A.C. and Eaves, C.J. (1990) Proc. Nat. Acad. Sci. U.S.A. 87, 3584–3588.
Cournoyer, D., Scarpa, M., Moore, K.A., Fletcher, F.A., MacGregor, G.R., Belmont, J.W. and Caskey, C.T. (1991) in Etiology of Human Disease at the DNA Level (J. Lindsten and U. Pettersson, eds.), pp. 199–220, Raven Press, New York, NY.
Culver, K.W., Anderson, W.F. and Blaese, R.M. (1991) Human Gene Therapy 2, 107–110.
Moseley, A., Mitani, K., Deisseroth, A. and Caskey, C.T. (1992) J. Cell. Biochem. (Suppl. 16F), 50.
Cournoyer, D., Scarpa, M., Mitani, K., Moore, K.A., Markowitz, D., Bank, A., Belmont, J.W. and Caskey, C.T. (1991) Human Gene Therapy 2, 203–213.
Barranger, J.A. and Ginns, E.I. (1989) in the Metabolic Basis of Inherited Disease, 6th Edition (C.R. Scriver, A.L. Beaudet, W.S. Sly and D. Valle, eds.), pp. 1677–1698, McGraw-Hill, New York, NY.
Ringdon, O., Groth, C.-D., Erickson, A., Backman, L., Granqvist, S., Mansson, J.-E. and Svennerholm, L. (1988) Transplantation 46, 66–70.
Barton, N.W., Furbish, F.S., Murray, G.J., Garfield, M. and Brady, R.O. (1990) Proc. Nat. Acad. Sci. U.S.A. 87, 1913–1916.
Kohn, D.B., Nolta, J.A., Wienthal, J., Bahner, I., Yu, X.J., Lilley, J. and Crooks, J.M. (1991) Human Gene Therapy 2, 101–106.
Correli, P.H., Kew, Y., Perry, L.K., Brady, R.O., Fink, J.K. and Karlsson, S. (1990) Human Gene Therapy 1, 277–288.
Weatherall, D.J., Clegg, J.B., Higgs, D.R. and Wood, W.G. (1989) in the Metabolic Basis of Inherited Disease (C.R. Scriver, A.L. Beaudet, W.S. Sly and D. Valle, eds.), pp. 2305–2339, McGraw-Hill, New York, NY.
de Montalembert, M., Llados, A., Hannadouche, T. and Girot, R. (1989) Arch. Fr. Pediatr. 46, 99–103.
Fosburg, M.T. and Nathan, D.G. (1990) Blood 76, 435–444.
Novak, U., Harris, E.A.S., Forrester, W., Groudine, M. and Gelinas, R. (1990) Proc. Nat. Acad. Sci. U.S.A. 87, 3386–3390.
Ledley, F.D. (1987) J. of Ped. 110, 167–174.
Ponder, K.P., Dunbar, R.P., Wilson, D.R., Darlington, G.J. and Woo, S.J.L. (1991) Human Gene Therapy 2, 41–52.
Grompe, M., Jones, S.N., Loulseged, H. and Caskey, C.T. (1992) Human Gene Therapy 3, 35–44.
Kay, M.A., Baley, P., Rothenberg, S., Leland, F., Fleming, L., Ponder, K.P., Liu, T.-J., Finegold, M., Darlington, G., Pokorny, W. and Woo, S.L.C. (1992) Proc. Nat. Acad. Sci. U.S.A. 89, 89–93.
Wilson, J.M., Chowdhury, N.R., Grossman, M., Wajsman, R., Epstein, A., Mulligan, R.C. and Chosdhury, J.R. (1990) Proc. Nat. Acad. Sci. U.S.A. 87, 8437–8441.
Ledley, F.D. (1991) Human Gene Therapy 2, 331–358.
Wilson, J.M. (1991) Federal Register Announcement, Human Gene Therapy 2, 378.
Goldstein, J.L. and Brown, M.S. (1989) in The Metabolic Basis of Inherited Disease, 6th Edition (C.R. Scriver, A.L. Beaudet, W.S. Sly and D. Valle, eds.), pp. 1215–1250, McGraw-Hill, New York, NY.
Grossman, M., Raper, S.E. and Wilson, J.M. (1991) Somatic Cell, and Mol. Genetics 17, 601–607.
Wilson, J.M., Grossman, M., Wu, C.H., Chowdhury, N.R., Wu, G.Y. and Chowdhury, J.R. (1992) J. Biol. Chem. 267, 963–967.
Brusilow, S.W. and Horwich, A.L. (1989) in The Metabolic Basis of Inherited Disease, 6th Edition (C.R. Scriver, A.L. Beaudet, W.S. Sly and D. Valle, eds.), pp. 629–670, McGraw-Hill, New York, NY.
Stratford-Perricaudet, L.D., Levero, M., Chasse, J.-F., Perricaudet, M. and Briand, P. (1990) Human Gene Therapy 1, 241–256.
Harper, P.S. (1989) in The Metabolic Basis of Inherited Disease, 6th Edition (C.R. Scriver, A.L. Beaudet, W.S. Sly and D. Valle, eds.), pp. 2869–2902, McGraw-Hill, New York, NY.
Leee, C.C., Pearlman, J.A., Chamberlain, J.S. and Caskey, C.T. (1991) Nature 349, 334–336.
Rossiter, B.J.F., Stirpe, N.S. and Caskey, C.T. (1992) Neurology 42, 1413–1418.
Verkerk, A.M.J.H., Pieretti, M., Sutcliffe, S., Fu, Y.-H., Kuhl, D.P.A., Pizzuti, A., Reiner, O., Richards, S., Victoria, M.F., Zhang, F., Eussen, B.E., Ommen, G.-J., Blonden, L.A.J., Riggins, G.J., Chastain, J.L., Kunst, C.B., Caskey, C.T., Nelson, D.L., Oostra, B.A. and Warren, S.A. (1991) Cell 65, 905–914.
Fu, Y.-H., Pizzuti, A., Fenwick, Jr., R.G., King, J., Rajnarayan, S., Dunne, P.W., Dubel, J., Nasser, G.A., Ashizawa, T., De Jong, P., Wieringa, B., Korneluk, R., Perryman, M.B., Epstein, H.F. and Caskey, C.T. (1992) Science 255, 1256–1258.
Rosenberg, S.A. (1992) J. Clin. Oncology 10, 180–199.
Rosenberg, S.A. (1990) Human Gene Therapy 1, 463–471.
Sorrentino, B.P., Brandt, S., Gottesman, M., Pastan, I., Bodine, D. and Nienhuis, A.W. (1991) Blood 78 (Suppl. 1), 191.
Caruso, M. and Klatzman, D. (1992) Proc. Nat. Acad. Sci. U.S.A. 89, 182–186.
Jolly, D.J. (1991) Human Gene Therapy 2, 111–112.
Jolly, D.J. (1992) Abstracts, 1992 Meeting on Gene Therapy (W.F. Anderson, T. Friedmann and R. Mulligan, eds.) Cold Spring Harbor Press, New York, NY.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1993 Springer Science+Business Media New York
About this chapter
Cite this chapter
Moseley, A.B., Caskey, C.T. (1993). Prospects for Human Gene Therapy. In: Setlow, J.K. (eds) Genetic Engineering. Genetic Engineering: Principles and Methods, vol 15. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-1666-2_10
Download citation
DOI: https://doi.org/10.1007/978-1-4899-1666-2_10
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4899-1668-6
Online ISBN: 978-1-4899-1666-2
eBook Packages: Springer Book Archive